Tuesday, February 7, 2017
FDA has lifted the partial clinical hold on Northwest Biotherapeutics’ phase 3 cancer vaccine trial. The action comes 18 months after FDA suspended the screening of new patients in the trial, and potentially just months before Northwest Bio hits the thresholds needed to wrap up the study.
Tuesday, February 7, 2017
After failing in an ulcerative colitis test a few years back, GW Pharma’s cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor.
Tuesday, February 7, 2017
Prexton Therapeutics has raised €29 million ($31 million) to take its Parkinson’s disease candidate through two phase 2 trials. The Series B positions the Merck Serono spinout to build on last year’s phase 1 success by testing the mGluR4 positive allosteric modulator in larger efficacy studies.
Tuesday, February 7, 2017
Gene therapy specialist Renova Therapeutics has strengthened its position in heart failure by licensing rights to an injectable peptide drug held by Janssen.
Monday, February 6, 2017
Allurion Technologies raised $19 million of a $27 million offering. The Natick, Massachusetts-based company markets an ingestible weight-loss balloon in parts of Europe and the Middle East.
Tuesday, February 7, 2017
Once again, we at FiercePharma and FierceBiotech are putting together a list of the year’s most influential people in biopharma. And we want your help.
Sponsored By: Veeva
Learn over a dozen best practices for deploying a global content system. Read Whitepaper.
Sponsored By: Veeva
Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper.
Sponsored By: Veeva
Learn How to Create a Unified RIM Environment for IDMP. Find out.
Sponsored By: Veeva
The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time.
Sponsored By: Salesforce
Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform.
Presented by: Patheon
Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more!
